Protective effects of xyloketal B against MPP+-induced neurotoxicity in Caenorhabditis elegans and PC12 cells

Brain Research

Volumn 1332, Issue , 2010, Pages 110-119

  Lu, Xi lin ^a   Yao, Xiao li ^a   Liu, Zhiyong ^a   Zhang, Heng ^a   Li, Wei ^a   Li, Zhenxing ^a,b   Wang, Guan Lei ^a,b   Pang, Jiyan ^a   Lin, Yongcheng ^a   Xu, Zhongliang ^a   Chen, Ling ^a   Pei, Zhong ^a   Zeng, Jinsheng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

C. elegans; Mitochondria; MPP+; ROS; Total GSH; Xyloketal B

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE RECEPTOR; GLUTATHIONE; GREEN FLUORESCENT PROTEIN; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; XYLOKETAL B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CAENORHABDITIS ELEGANS; CELL DAMAGE; CELL STRAIN; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG SCREENING; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CELL NUCLEUS; CELL SURVIVAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; GREEN FLUORESCENT PROTEINS; INTRACELLULAR SPACE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PC12 CELLS; PYRANS; RATS; REACTIVE OXYGEN SPECIES;

CAENORHABDITIS ELEGANS; FUNGI; XYLARIA;

EID: 77951641666     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.03.071     Document Type: Article

References (36)

1. Abdel-Salam O.M. Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol. Disord. Drug Targets 7 (2008) 321-342
2. Anantharam V., Kaul S., Song C., Kanthasamy A., and Kanthasamy A.G. Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology 2007 28 (2007) 988-997
3. Aoyama K., Matsumura N., Watabe M., and Nakaki T. Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction. Eur. J. Neurosci. 27 (2008) 20-30
4. Banerjee R. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 1792 7 (2009) 651-663
5. Braungart E., Gerlach M., Riederer P., Baumeister R., and Hoener M.C. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener. Dis. 1 (2004) 175-183
6. Cassarino, D.S., 1999. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta. 6;1453(1):49-62.
7. Chen W.L., Qian Y., Meng W.F., Pang J.Y., Lin Y.C., Guan Y.Y., Chen S.P., Liu J., Pei Z., and Wang G.L. A novel marine compound xyloketal B protects against oxidized LDL-induced cell injury in vitro. Biochem. Pharmacol. 78 (2009) 941-950
8. Chiba K., Trevor A.J., and Castagnoli N.J. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 128 (1985) 1228-1232
9. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
10. Di Monte D., Sandy M.S., and Smith M.T. Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Biochem. Biophys. Res. Commun. 148 (1987) 153-160
11. Ebadi M., and Sharma S.K. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid. Redox Signal. 5 3 (2003) 319-335
12. Henchcliffe C., and Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4 (2008) 600-609
13. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T., Liu R.M., Forman H.J., and Andersen J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J. Biol. Chem. 275 (2000) 26096-26101
14. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
15. Lee C.S. Modulation of 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells by K(ATP) channel block. J. Neural Transm. 114 (2007) 297-305
16. Link C.D. Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech. Ageing Dev. 122 (2001) 1639-1649
17. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275 (2000) 38581-38588
18. Mandemakers W., Morais V.A., and De Strooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell Sci. 120 (2007) 1707-1716
19. Marongiu M.E., Piccardi M.P., Bernardi F., Corsini G.U., and Del Zompo M. Evaluation of the toxicity of the dopaminergic neurotoxins MPTP and MPP+ in PC12 pheochromocytoma cells: binding and biological studies. Neurosci. Lett. 94 (1988) 349-354
20. Martin H.L., and Teismann P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J. 2009 23 (2009) 3263-3272
21. Nicotra A., and Parvez S. Apoptotic molecules and MPTP-induced cell death. Neurotoxicol. Teratol. 24 (2002) 599-605
22. Nass R., and Blakely R.D. The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 521-544
23. Nass R., Hall D.H., Miller III D.M., and Blakely R.D. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3264-3269
24. Presse F., Cardona B., Borsu L., and Nahon J.L. Lithium increases melanin-concentrating hormone mRNA stability and inhibits tyrosine hydroxylase gene expression in PC12 cells. Brain Res. Mol. Brain Res. 52 (1997) 270-283
25. Pu P., and Le W. Dopamine neuron degeneration induced by MPP+ is independent of CED-4 pathway in Caenorhabditis elegans. Cell Res. 18 (2008) 978-981
26. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
27. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., and Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44 (1998) S89-S98
28. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M., and Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59 (2002) 1541-1550
29. Storch A., Ludolph A.C., and Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural Transm. 111 (2004) 1267-1286
30. Tetrud J.W., and Langston J.W. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol. Scand. Suppl. 126 (1989) 35-40
31. Wang H., and Joseph J.A. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med. 27 (1999) 612-616
32. Vitvitsky V. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J. Biol. Chem. 281 (2006) 35785-35793
33. Yamamoto N. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J. Biol. Chem. 282 (2007) 4364-4372
34. Zachor D.A., Moore J.F., Brezausek C., Theibert A., and Percy A.K. Cocaine inhibits NGF-induced PC12 cells differentiation through D(1)-type dopamine receptors. Brain Res. 869 (2000) 85-97
35. Zeevalk G.D. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp. Neurol. 203 (2007) 512-520
36. Zhao J., Li L., Ling C., Li J., Pang J.Y., Lin Y.C., Liu J., Huang R., Wang G.L., Pei Z., and Zeng J. Marine compound Xyloketal B protects PC12 cells against OGD-induced cell damage. Brain Res. 1302 (2009) 240-247